Table 3 Inhibitor used as new therapeutic approaches for osteosarcoma in clinical trails (Multitarget inhibitors, IGF1-R inhibitors, mTOR inhibitors and inhibitor of Wnt/β-catenin signaling)
From: Novel molecular insights and new therapeutic strategies in osteosarcoma
Status | Conditions | Interventions | Phase | Last update posted |
|---|---|---|---|---|
Unknown | Osteosarcoma | Drug: Chemotherapy Drug: Endostar (drug type: VEGFR inhibitor) | Phase 2 | September 3, 2014 |
Completed | Osteosarcoma | Drug: sorafenibb (multi target inhibitor: PRGFR/VEGFR inhibitor) | Phase 2 | March 28, 2013 |
Recruiting | Soft tissue sarcoma Bone sarcoma | Sunitinib [Sutent] (multitarget inhibitors: (e.i.,PDGF-Rs, VEGFRs) | Phase 1 | September 11, 2017 |
| Â | Metastatic osteosarcoma Relapsed osteosarcoma | Drug: Sorafenibb (multitarget inhibitors; PRGFR/VEGFR inhibitor) Drug: Everolimus (mTOR inhibitor) | Phase 2 | June 17, 2015 |
Completed | Sarcoma | Drug: RG1507 (IGF1-R inhibitors) | Phase 2 | April 4, 2017 |
Completed | Sarcoma | Drug: RG1507(IGF1-R inhibitors) | Phase 2 | April 4, 2017 |
Unknown | Osteosarcoma | Dietary supplement: Curcumin powder (WNT/β-catenin inhibitor) Dietary Supplement: Ashwagandha extract | Phase 1 Phase 2 | June 23, 2011 |
Completed | Osteosarcoma | Drug: Saracatinib a Src inhibitor of c-Src) Drug: Placebo | Phase 2 | May 11, 2018 |
Terminated | Osteosarcoma Metastatic osteosarcoma | Drug: Pazopanibc (drug type: multitarget inhibitors: VEGFR inhibitor) | Phase 2 | June 26, 2018 |
Unknown | Refractory or relapsed osteosarcoma | Drug: Everolimus (mTOR inhibitor) | Phase 2 | August 7, 2013 |
Completed | Osteosarcoma Metastasis | Drug: Apatinib (YN968D1, tyrosine kinase inhibitor and VEGFR2 inhibitor) | Phase 2 Phase 3 | April 23, 2018 |
Active, not recruiting | Osteosarcoma Malignant fibrous histiocytoma (MFH) of bone | Biological: Bevacizumab (drug type: monoclonal antibody; target: VEGF-A) Drug: Cisplatin Drug: Doxorubicin (and 5 more…) | Phase 2 | June 14, 2018 |
Completed | Sarcoma | Biological: trastuzumab (drug type: monoclonal antibody; target: ERBB2) Procedure: conventional surgery | Phase 2 | June 21, 2013 |
Terminated | Osteosarcoma Sarcoma, Ewing’s Peripheral neuroectodermal tumor | Biological: Robatumumab (SCH 717454; IGF1-R inhibitors ) | Phase 2 | June 7, 2017 |
Recruiting | Metastatic Ewing sarcoma Metastatic osteosarcoma Recurrent Ewing sarcoma (and 7 more…) | Drug: Cabozantinib S-malate (small molecule receptor tyrosine kinase (RTK) inhibitor) | Phase 2 | May 24, 2018 |
Recruiting | Ewing sarcomas Chondrosarcomas Osteosarcomas Chondroma | Drug: Regorafenib (multi-kinase inhibitor Drug: Placebo | Phase 2 | August 16, 2018 |
Completed | Metastatic soft-tissue sarcomas Metastatic bone sarcomas | Drug: Ridaforolimus (mTOR inhibitor) Drug: Placebo | Phase 3 | February 13, 2015 |
Recruiting | Adult liposarcoma Metastatic liposarcoma Metastatic osteosarcoma (and 4 more…) | Drug: Pazopanibc hydrochloride (multitarget inhibitors; target: PDGFR, c-Kit,) Drug: Oral Topotecan hydrochloride | Phase 2 | January 9, 2018 |
Completed has results | Metastatic osteosarcoma Recurrent adult soft tissue sarcoma Recurrent osteosarcoma (and 2 more…) | Biological: Cixutumumab ( drug type: monoclonal antibody; target: IGF1R) Drug: Temsirolimus | Phase 2 | July 30, 2015 |
Completed | Childhood malignant fibrous histiocytoma of bone Sarcoma | Drug: Imatiniba mesylate (PDGFR inhibitor) | Phase 2 | June 19, 2013 |
Completed | Glioblastoma Rhabdomyosarcomas Neuroblastoma Osteosarcoma | Drug: Irinotecan (Camptosar), Gefitinib (ZD1839: Drug type: EGFR inhibitor )or (Iressa) | Phase 1 | April 17, 2012 |
Terminated has results | Sarcoma | Drug: Sorafenibb (PRGFR/VEGFR inhibitor) Drug: Ifosfamide | Phase 2 | November 24, 2015 |
Recruiting | Liposarcoma Osteogenic sarcoma Ewing/Ewing-like sarcoma Rhabdomyosarcoma | Drug: Regorafenib Drug: Placebo | Phase 2 | July 18, 2018 |
Completed | Leiomyosarcoma Liposarcoma Osteosarcoma (and 2 more…) | Drug: Ridaforolimus (mTOR inhibitor) | Phase 2 | February 13, 2015 |
Completed | Sarcoma | Drug: RG1507 (drug type: monoclonal antibody; Target: IGF1R ) | Phase 2 | April 4, 2017 |
Withdrawn | Sarcoma Neuroblastoma Wilms tumor (and 2 more…) | Drug: Pazopanibc (drug type: VEGFR inhibitor), (GW786034) | Phase 1 | July 2, 2017 |
Completed has results | Metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor Metastatic osteosarcoma Recurrent adult soft tissue sarcoma (and 6 more…) | Drug: Sorafenibb tosylate (multitarget inhibitors: PRGFR/VEGFR inhibitor) Procedure: Therapeutic conventional surgery Other: Laboratory biomarker analysis (and 3 more…) | Phase 2 | April 30, 2014 |
Recruiting | Glioma Rhabdomyosarcoma Osteosarcoma (and 5 more…) | Biological: Erlotinib (drug type: PDGFR Inhibitor) Drug: Temozolomide | Phase 2 | February 15, 2018 |